Incredible development -- FDA Fast Track Designation! Investors who have followed this company for a long time are aware of the many years of progress on the books that MultiStem has made for extending the treatment window for Ischemic Stroke and for improving patient outcomes following a stroke. This is just incredibly significant. The market is sound asleep on this information. But this news can't stay quiet long. Management stated this week that the FDA now is pushing ATHX forward complete Phase III and, at the same time, a similar study is also moving forward in Japan. Per the most recent SEC filing: "We completed our Phase 2 study of MultiStem treatment of patients suffering a moderate to severe ischemic stroke and announced the one-year follow-up data and final results from the study in February 2016. We are actively engaged in advancing the next stage of clinical development of this program, both independently and with HEALIOS K.K., or Healios. In September 2016, we announced that we received agreement from the U.S. Food and Drug Administration, or FDA, under a Special Protocol Assessment, or SPA, for the design and planned analysis of a pivotal Phase 3 clinical trial of MultiStem cell therapy for the treatment of ischemic stroke. With the announcement of the FDA Fast Track designation, this pivotal trial will begin shortly. Management also announced gearing up of its manufacturing/processing operations, a clear signal that MultiStem will reach the market. With no competition to fulfill this urgent unmet need, MultiStem presents us with a unique investment opportunity. Low entry points won't be here once the bloggers start spreading the word.
